Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM6Q7U4)

Drug Name
Lenalidomide Drug Info
Synonyms
Revamid; Revimid; Revlimid; Celgene brand of lenalidomide; Lenalidomide [USAN]; CC 5013; CC5013; CDC 501; IMiD3; IMiD3cpd; ALBB-015321; CC-5013; CDC-501; CDC-5013; ENMD-0997; IMID-5013; Revlimid (Celgene); Revlimid (TN); Thalidomide analog CC-5013; Lenalidomide (USAN/INN); CC-5013, Revlimid, Lenalidomide; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Lenalidomide (Immunomodulator)
Therapeutic ClassAnticancer Agents
Cross-matching ID
PubChem CID
216326
ChEBI ID
CHEMBL848
CAS Number
CAS 191732-72-6
TTD Drug ID
D0Q5NX
VARIDT Drug ID
DR00261
ACDINA Drug ID
D00353

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Ribosome biogenesis in eukaryotes 2.41 0.00e+0 52/108 (48.15%) RPP38;POP7;IMP3;...
DNA replication 2.34 0.00e+0 34/36 (94.44%) FEN1;POLE2;PCNA;...
Cell cycle 2.31 0.00e+0 110/124 (88.71%) CDC20;PLK1;CCNA2;...
Fanconi anemia pathway 2.21 0.00e+0 36/54 (66.67%) CENPX;BRCA1;RAD51;...
Proteasome 2.11 1.16e-3 44/46 (95.65%) PSMC3;PSMD8;PSMD14;...
RNA transport 2.04 1.93e-3 128/186 (68.82%) NUP37;RPP38;POP7;...
Spliceosome 2.04 1.65e-3 101/150 (67.33%) HSPA8;LSM6;LSM3;...
Homologous recombination 2.00 2.89e-3 35/41 (85.37%) BRCA1;RAD51;RAD51C;...
Oocyte meiosis 1.95 2.57e-3 90/129 (69.77%) CDC20;PLK1;CCNB1;...
Progesterone-mediated oocyte maturation 1.93 2.31e-3 75/100 (75%) PLK1;CCNA2;CCNB1;...
Mismatch repair 1.87 4.20e-3 22/23 (95.65%) PCNA;RFC3;MSH6;...
RNA degradation 1.86 4.33e-3 53/79 (67.09%) BTG3;LSM6;LSM1;...
RNA polymerase 1.81 5.78e-3 23/31 (74.19%) POLR3K;POLR2D;POLR2I;...
Pyrimidine metabolism 1.78 8.26e-3 40/56 (71.43%) RRM2;NME1;UMPS;...
p53 signaling pathway 1.72 1.58e-2 63/73 (86.3%) CYCS;CCNB1;RRM2;...
Base excision repair 1.68 2.42e-2 29/33 (87.88%) FEN1;POLE2;PCNA;...
Salivary secretion -1.66 4.69e-2 76/93 (81.72%) BST1;ADCY6;SLC12A2;...
Insulin secretion -1.67 4.81e-2 75/86 (87.21%) PRKCA;CREB5;GNA11;...
TNF signaling pathway -1.67 4.84e-2 103/112 (91.96%) VEGFC;RELA;MMP3;...
Phosphatidylinositol signaling system -1.68 4.75e-2 82/97 (84.54%) PLCD1;DGKZ;PIP5K1C;...
Sulfur metabolism -1.70 3.92e-2 9/10 (90%) PAPSS1;SQOR;SELENBP1;...
Mitophagy -1.71 3.88e-2 56/68 (82.35%) NBR1;TAX1BP1;BNIP3;...
Thyroid hormone synthesis -1.72 4.12e-2 66/75 (88%) TSHB;DUOX1;SLC26A4;...
IL-17 signaling pathway -1.72 4.42e-2 84/94 (89.36%) IL17RB;MUC5B;RELA;...
Notch signaling pathway -1.74 4.23e-2 49/59 (83.05%) APH1A;MAML1;RFNG;...
Inositol phosphate metabolism -1.75 4.63e-2 66/73 (90.41%) PLCD1;PIP5K1C;INPP5K;...
Amoebiasis -1.77 4.17e-2 99/102 (97.06%) ARG2;LAMA2;RELA;...
Coronavirus disease -2.01 1.47e-2 215/232 (92.67%) RPL30;MAPK9;RPL17;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 200uM 6H
Bone marrow
Chronic myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
K-562 CVCL_0004 Homo sapiens 0.01uM - 10uM 4H, 24H
Multiple myeloma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
KMS-34 CVCL_1333 Homo sapiens 0.01uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 200uM 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 200uM 6H
HT-29 CVCL_0320 Homo sapiens 0.01uM - 200uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 200uM 6H
MDST8 CVCL_1400 Homo sapiens 200uM 6H
NCI-H508 CVCL_1561 Homo sapiens 200uM 6H
SNU-1040 CVCL_5001 Homo sapiens 200uM 6H
SNU-C4 CVCL_5008 Homo sapiens 200uM 6H
SNU-C5 CVCL_5009 Homo sapiens 200uM 6H
SW480 CVCL_0546 Homo sapiens 200uM 6H
SW620 CVCL_0547 Homo sapiens 200uM 6H
SW948 CVCL_0550 Homo sapiens 200uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 200uM 6H
HT115 CVCL_1294 Homo sapiens 200uM 6H
RKO CVCL_0504 Homo sapiens 200uM 6H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 200uM 6H
SNG-M CVCL_1707 Homo sapiens 200uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 200uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 200uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM - 200uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 200uM 6H, 24H
DV-90 CVCL_1184 Homo sapiens 200uM 6H
SK-LU-1 CVCL_0624 Homo sapiens 200uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 200uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 200uM 6H
T3M-10 CVCL_1729 Homo sapiens 200uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC15 CVCL_1253 Homo sapiens 200uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 200uM 6H
HCC515 CVCL_5134 Homo sapiens 10uM - 200uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 200uM 6H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 200uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 200uM 6H
Lymph node
Burkitt lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BJAB CVCL_5711 Homo sapiens 0.01uM - 10uM 4H
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HBL-1 CVCL_4213 Homo sapiens 0.01uM - 10uM 4H, 24H
OCI-Ly10 CVCL_8795 Homo sapiens 0.01uM - 10uM 24H
OCI-Ly19 CVCL_8797 Homo sapiens 0.01uM - 10uM 4H, 24H
OCI-Ly3 CVCL_8796 Homo sapiens 0.01uM - 10uM 4H, 24H
TMD8 CVCL_A440 Homo sapiens 0.01uM - 10uM 4H, 24H
WSU-DLCL2 CVCL_1787 Homo sapiens 200uM 6H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 200uM 6H
OV7 CVCL_1623 Homo sapiens 200uM 6H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RMG-I CVCL_1663 Homo sapiens 200uM 6H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV644 CVCL_2011 Homo sapiens 200uM 6H
RMUG-S CVCL_1666 Homo sapiens 200uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 200uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 6H, 24H
Peripheral blood
Acute B-lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NALM-6 CVCL_0092 Homo sapiens 0.01uM - 10uM 24H
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 200uM 4H, 6H, 24H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NOMO-1 CVCL_1609 Homo sapiens 200uM 6H
PL-21 CVCL_2161 Homo sapiens 200uM 6H
SKM-1 CVCL_0010 Homo sapiens 200uM 6H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 200uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 200uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM - 200uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 200uM 6H, 24H
SK-MEL-1 CVCL_0523 Homo sapiens 200uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 200uM 6H
SK-MEL-5 CVCL_0527 Homo sapiens 0.01uM - 10uM 24H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 200uM 6H